Treatment of Metabolic Alkalosis with Hypertension, Hypokalemia, and High Mineralocorticoid States
This protocol addresses metabolic alkalosis presenting with intravascular volume expansion, urine chloride above 20 mmol/L, elevated blood pressure, and hypokalemia — a pattern driven by high mineralocorticoid activity. Unlike volume-depleted (chloride-responsive) alkalosis, this subtype requires a fundamentally different approach.
Clinical Scenario
The defining features are urine chloride exceeding 20 mmol/L (chloride resistance), intravascular volume expansion rather than depletion, hypertension, and concurrent hypokalemia — all consistent with excess mineralocorticoid activity as the underlying driver.
Management Approach
Management is directed at identifying and modifying the primary source of mineralocorticoid excess — whether through surgical or pharmacological means — alongside targeted correction of the potassium deficit. The full structured protocol, including treatment sequencing and specific intervention criteria, is available via the link below.
Clinical Goal
Correction of hypokalemia, with normalisation of serum potassium as the key marker of response.
References
DOI: 10.1053/j.ajkd.2021.12.016
- The treatment of metabolic alkalosis with volume expansion (urine Cl− > 20 mmol/L and elevated blood pressure) is mainly directed at modification of the primary cause when associated with high mineralocorticoid states, and the correction of hypokalemia.
- Almost all cases of Cl−-resistant alkalosis are associated with hypokalemia; therefore, the correction of K+ deficiency is essential to diminish the severity of metabolic alkalosis.
- Removing the source of mineralocorticoid excess, as in adrenal or pituitary tumors, is the cornerstone of this therapy.
- In other cases, such as in primary hyperaldosteronism, treatment could be pursued via direct hormone blockade with the use of mineralocorticoid receptor antagonists (eg, spironolactone, eplerenone) or via amiloride, an ENaC blocker.
- The judicious use of oral or intravenous K+ supplementation is advised, depending on the severity of the hypokalemia.
View source ↗